Journal of Clinical Endocrinology & Metabolism, Vol 77, 199-204, Copyright © 1993 by Endocrine Society

ARTICLES

Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy controls

EM Rutanen, S Stenman, W Blum, T Karkkainen, P Lehtovirta and UH Stenman
Department I Of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland.

Insulin is a major regulator of circulating insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1), suppressing the hepatic production of IGFBP-1. Postmenopausal age, obesity, hypertension, and impaired glucose tolerance, which are known risk factors for endometrial cancer, are all associated with hyperinsulinemia and insulin resistance. In this study, we investigated the relationship among serum insulin, glucose, insulin-like growth factors (IGF-I and IGF-II), and IGFBP-, - 2, and -3 in 32 nondiabetic postmenopausal women with endometrial cancer and in 18 healthy controls. The mean fasting levels of glucose and insulin were higher, whereas the mean basal IGF-I, IGF-II, and IGFBP-3 levels were lower in the endometrial cancer patients than in the healthy control subjects. The mean fasting IGFBP-1 and IGFBP-2 levels did not differ between the groups, and no correlation was found between fasting insulin and IGFBP-1 concentrations or between insulin and IGFBP-2 concentrations in either of the study groups. During an oral glucose tolerance test, the mean glucose levels at 1 and 3 h as well as the mean insulin level at 3 h were significantly higher in the endometrial cancer patients than in the controls, and the area under the glucose curve was larger in the first group. An oral glucose load resulted in a similar fall in serum IGFBP-1 levels in endometrial cancer patients and controls (51% and 55% at 3 h). When the cancer patients were divided into two subgroups according to the body mass index (kilograms per m2), the obese group had higher glucose and insulin indices than the nonobese group. No difference was found by the same measures in healthy controls. The fasting serum IGFBP-1 levels tended to be lower in the obese than in the normal weight subjects, but the difference did not reach statistical significance. In summary, these results provide preliminary evidence that the inverse relation between fasting insulin and IGFBP-1, well established in children and young adults, disappears in elderly women, although short term suppression by insulin still occurs. Further, our data indicate that in addition to carbohydrate metabolism, postmenopausal women with endometrial cancer have alterations in their circulating IGF system compared to controls.

This article has been cited by other articles:

				A. E Cust, R. Kaaks, C. Friedenreich, F. Bonnet, M. Laville, A. Tjonneland, A. Olsen, K. Overvad, M. U. Jakobsen, V. Chajes, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Endocr. Relat. Cancer, September 1, 2007; 14(3): 755 - 767. [Abstract] [Full Text] [PDF]

				J. V. Lacey Jr., N. Potischman, M. P. Madigan, M. L. Berman, R. Mortel, L. B. Twiggs, R. J. Barrett, G. D. Wilbanks, J. R. Lurain, C.-M. Fillmore, et al. Insulin-Like Growth Factors, Insulin-Like Growth Factor-Binding Proteins, and Endometrial Cancer in Postmenopausal Women: Results from a U.S. Case-Control Study Cancer Epidemiol. Biomarkers Prev., April 1, 2004; 13(4): 607 - 612. [Abstract] [Full Text] [PDF]

				E. Petridou, C. Mantzoros, N. Dessypris, P. Koukoulomatis, C. Addy, Z. Voulgaris, G. Chrousos, and D. Trichopoulos Plasma Adiponectin Concentrations in Relation to Endometrial Cancer: A Case-Control Study in Greece J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 993 - 997. [Abstract] [Full Text] [PDF]

				R. Kaaks, A. Lukanova, and M. S. Kurzer Obesity, Endogenous Hormones, and Endometrial Cancer Risk: A Synthetic Review Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1531 - 1543. [Abstract] [Full Text] [PDF]

				G. E. Hale, C. L. Hughes, and J. M. Cline Endometrial Cancer: Hormonal Factors, the Perimenopausal ""Window of Risk,"" and Isoflavones J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 3 - 15. [Abstract] [Full Text] [PDF]

				A. Hoeflich, R. Reisinger, H. Lahm, W. Kiess, W. F. Blum, H. J. Kolb, M. M. Weber, and E. Wolf Insulin-like Growth Factor-binding Protein 2 in Tumorigenesis: Protector or Promoter? Cancer Res., December 1, 2001; 61(24): 8601 - 8610. [Full Text] [PDF]

				H. Yu and T. Rohan Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489. [Abstract] [Full Text] [PDF]